Skip to main content
Premium Trial:

Request an Annual Quote

QIMR Berghofer Partners With Liquid Biopsy Startup Biopsomic on Cancer Test

NEW YORK — Australia's QIMR Berghofer Medical Research Institute said on Sunday that it has partnered with liquid biopsy startup Biopsomic to develop a blood test for predicting a cancer patient's response to treatment.

According to QIMR Berghofer, the test will be designed to analyze tumor-derived exosomes. The alliance includes a technology licensing and option agreement, under which QIMR Berghofer will conduct collaborative research with Lausanne, Switzerland-based Biopsomic.

Financial and other terms of the arrangement were not disclosed.

"At the moment, clinicians have no reliable way of predicting whether a particular patient will respond better to chemotherapy, immunotherapy, or any other therapy," Andreas Möller, head of QIMR Berghofer's tumor micro-environment research group, said in a statement. "This blood test could quickly and accurately indicate the most effective treatment for an individual patient."